MRGN advisors brings decades of expertise in both multinational and start-up vaccine companies, and a worldwide network of experts spanning the entire value chain of vaccines, delivering cutting-edge solutions for research, development, manufacturing, regulatory, market access and immunization policy strategies.
Illustrative assignments performed recently:
Setup of technology partnership resting on unique production and formulation technologies, aiming at creating a new alternative to incumbent vaccines in the largest market segment.
Read more
Access business intelligence on selected vaccines or topics
Consider expanding the registration footprint and the business
opportunity for BCG-IT (High concentration BCG vaccine used to treat Non-Muscle Invasive Bladder Cancer)
Business intelligence matters cannot be disclosed due to confidentiality reasons.
Review of the competitive landscape, of the R&D pipeline in the first line treatment of NMIBC, and of the treatment guidelines. Identification of Key Opinion Leaders in selected European countries to form a scientific advisory board and craft the medical and regulatory strategy towards expanding the number of registrations in Europe.
Assessment of several investment opportunities in the life science sector, all of them being large M&A transactions (over EUR 100 million in r equired financing).
Specific information cannot be disclosed due to confidentiality reasons.
In general, these files involved performing in-depth due diligence,
collecting relevant business intelligence though network connections,
elaborating financial forecast models and contributing to final investment recommendations.
Support the preparation of the clinical development and commercial
strategy for a universal influenza vaccine candidate.
The detailed content of the contribution cannot be disclosed due to
confidentiality reasons. The asset was eventually transferred to a novel company spun-out from Imaxio, named Osivax. The collaboration was extended to supporting the series A financing, until the appointment of Pierre Morgon to the board of Vaccitech led to the termination of this collaboration (Vaccitech has a clinical-stage vaccine candidate in the same indication).
Support to series A financing by introducing the company to institutional, high net worth and other sophisticated investors, business angels and private investors, and venture capital.
Analysis of the fast-evolving competitive landscape (HIV vaccine candidates) and of the proposed positioning of the company asset. Finetuning of the investor pitch documents and execution of several investor presentations.
The board of the company eventually opted for a strategic reorientation and for management changes.
Perform a comprehensive analysis of the business opportunity for vaccines in the traveler segment in Europe.
Delivery of a complete recommendation including an analysis of available vaccine candidates, a review of ongoing R&D projects with a realistic probability of success, and a detailed revenue forecast.
